This initiative will provide the necessary investment to promote Apabetalone, a similar pioneering drug in the Arab-African economy that may be used to treat COVID-19.
Calgary, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE)-Resverlogix Corp. (hereinafter referred to as "Resverlogix" or the company ") (TSX: RVX), a global leader in epigenetics or gene regulation, is pleased to announce today that it has signed a cooperation agreement with the Supreme Arab-African Economic Council, which expresses interest in providing the necessary investments and partnerships. To support the introduction of Apabetalone, a similar pioneering drug of Resverlogix, into the Arab-African economy.
Donald J. McCaffrey, President and CEO of Resverlogix, said: "We are pleased to be able to work with the Supreme Arab-African Economic Council under the leadership of his Excellency Dr. Hani Abu Zaid." Mr. McCaffrey further commented: "the signing of this cooperation agreement will help us strengthen our relations, development and interests in the Arab-African economy, while promoting the development of Apabetalone."
His Excellency Dr. Hani Abu Zaid, Chairman of the Supreme Arab-African Economic Council, said: "the Supreme Arab-African Economic Council is pleased to cooperate with Resverlogix to provide it with the necessary investment and assistance to support Apabetalone's entry into the Arab-African economy. We look forward to working with Mr. McCaffrey and his team of world-class scientists and experts in the field of epigenetics. "
Resverlogix has been actively working with hospitals and departments around the world to launch COVID-19 clinical trials. On October 12, 2021, the Canadian Ethics Committee approved Resverlogix to conduct phase II clinical trials of Apabetalone in the treatment of COVID-19 patients at various locations in Western Canada. On November 1, 2021, the Canadian branch of the trial began actively recruiting patients. In addition, according to the approval of the final agreement, the United States is expected to launch three phases of COVID-19 trials in the coming months.
2Summary of phase test——Canada/Brazil
The participants in the study will be made up of hospitalized patients who have been diagnosed with COVID-19. Participants will receive Apabetalone twice a day for 4 weeks while receiving standard care, while the control group will only receive standard care. The main measure of the results of the study was the change in the score of the World Health Organization (WHO) Clinical improvement sequence scale. It is expected that 100 patients will participate in the study at multiple locations in Canada and Brazil. The study is actively recruiting people from branch offices in Canada. The complete research protocol can be found at clinicaltrials.gov.
About Arabia-Supreme Council of African economy——The directive of the committee
The Supreme Arab-African Economic Council is an economic-diplomatic body recognized by the United Nations, the European Union, the Arab League and the Common Market for South-East Africa (COMESA). The Supreme Arab-African Economic Council focuses on enhancing and promoting investment and trade among member States and their subsidiary bodies in order to strengthen their economies.
AboutApabetalone
Apabetalone (RVX-208) is the first candidate drug for epigenetic small molecule or gene regulation therapy. This is a selective BET (Bromine domain和Hyperterminal domain) inhibitors that regulate gene expression by turning on and / or off genes to prevent disease. BET protein is ubiquitous in the human body, which enables Apabetalone to target a variety of biological processes that lead to diseases through its unique mechanism, and maintain good safety, so as to achieve new methods for the treatment of chronic diseases.
Cardiology:
In February 2020, following the breakthrough results of BETonMACE Phase III study, Apabetalone became the first treatment drug to be approved by the U.S. Food and Drug Administration (FDA) as a breakthrough therapy for a major cardiovascular indication. Data from BETonMACE show that Apabetalone is expected to prevent major adverse cardiac events in patients with high-risk cardiovascular disease who also have type 2 diabetes.
COVID-19:
On March 23, 2020, Resverlogix and world-renowned partners jointly launched its COVID-19 project. Studies have shown that Apabetalone is expected to fight COVID-19 through a unique dual mechanism: the first pillar of the dual mechanism of Apabetalone is to prevent the virus from entering the cell and replicating, and the second pillar is to avoid inflammation that can lead to severe and lasting organ damage. A phase 2 clinical trial is evaluating Apabetalone in conjunction with standard care for COVID-19 's hospitalized patients. Apabetalone treatment is expected to reduce the severity and duration of COVID-19 's epidemic. Apabetalone's unique dual mechanism also means that it may show efficacy against novel coronavirus variants and may even help fight other related viruses.
Apabetalone is the only drug in its category with a good safety record in human clinical trials, with more than 4200 patient years in 10 clinical trials.
AboutResverlogix
Founded in 2001, Resverlogix is a late-stage biotechnology company headquartered in Calgary and a global leader in epigenetics or gene regulation, with the goal of developing similar innovative therapies for the benefit of people with chronic diseases.
Resverlogix is commercializing a new class of epigenetic therapy that aims to regulate gene expression by "turning on" or "turning off" disease-related genes. Our aim is to improve the lives of patients by restoring biological functions changed by serious diseases such as cardiovascular disease to a healthier state.
The company's clinical plan focuses on evaluating the main epigenetic drug candidate Apabetalone, which is used to treat cardiovascular disease and related coexisting diseases, as well as COVID-19.
Resverlogix's common stock is listed on the Toronto Stock Exchange (TSX: RVX).
Follow us: Twitter:@Resverlogix_RVX.
LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For more information, please contact:
Investor relations
Email: ir@resverlogix.com
Tel: 403254-9252
Www.resverlogix.com
Forward-looking statements
This press release may contain certain forward-looking information as defined by applicable Canadian securities law, which is not based on historical facts, including, but not limited to, statements containing the following terms:“Think that”、“Expected”、“plan”、“Intentionally”、“Be about to”、“应”、“Expectation”、“Go ahead”、“Estimation”、“Forecast”And similar expressions. In particular, this press release contains forward-looking information related to the following: the company and the Arab-Discussions of the Supreme Economic Council of Africa, clinical trials conducted by companies,ApabetalonePossible role in the treatment of patients with COVID-19 (and other viruses), cardiovascular diseases and related coexisting diseases, as well as other chronic diseases. Our actual results, events or developments may differ materially from those expressed or implied by these forward-looking statements. We cannot guarantee the occurrence or expected realization of the event. By its nature, forward-looking statements are subject to many assumptions and risk factors, including those discussed in our annual information sheet and recent management discussions and analysis, which are included in the references to this article. You can also use theWww.sedar.comVisitSEDARGet the relevant content. Forward-looking statements contained in this press release are expressly limited by this cautionary statement and are made as of the date of this release. Except as required by law, the Company has no obligation or obligation to update or revise any forward-looking statements as a result of new information, future events or other reasons.
The photos attached to this announcement are available on the following website: https://www.globenewswire.com/NewsRoom/AttachmentNg/85e7be23-a763-4133-be0c-e8fed603ecc8